群岛状角膜炎的临床病程与治疗:一种疱疹病毒性角膜炎亚型
该研究报告了2011至2021年两家中心82例(83眼)群岛状角膜炎(ApK)患者的临床特征、病程演变及复发相关因素。中位随访期间53%的患眼至少复发一次,复发与新生血管化、糖皮质激素减量及伐昔洛韦使用相关;所有患者均接受抗病毒治疗,88%联合局部抗炎药物,局部环孢素可作为减少糖皮质激素用量的治疗选择。
要点
- ApK典型表现为单侧,76%患者至少满足一项提示疱疹病因的次要诊断标准。
- 53%患眼在中位12个月后复发,复发与新生血管化(HR 2.1)、激素减量(HR 3.5)及伐昔洛韦使用(HR 2.3)相关。
- 所有患者均用抗病毒治疗,88%联合局部抗炎药,局部环孢素可作为减少激素用量的选择。
核心结论
- ApK是一种典型单侧发病、复发风险高的疱疹病毒性角膜基质炎,通常需要长期联合抗病毒与抗炎治疗,局部环孢素可作为减少糖皮质激素用量的治疗选择。
研究设计与样本
- 回顾性分析2011至2021年两家中心82例(83眼)诊断为ApK患者的临床记录。
主要发现
- 82例患者就诊时中位年龄为37±28岁,除1例外均为单侧发病。
- 76%的患者至少有一项提示疱疹病因的次要诊断标准。
- 44眼(53%)在中位12个月后至少复发一次。
- 复发与新生血管化(HR 2.1,95%CI 1.1至3.9;p=0.02)相关。
- 复发与糖皮质激素减量(HR 3.5,95%CI 1.8至7.1;p<0.01)或伐昔洛韦使用(HR 2.3,95%CI 1.2至4.6;p=0.01)相关。
关键数值与推荐
- 所有患者均接受抗病毒治疗。
- 73例(88%)使用局部抗炎药物(糖皮质激素和/或环孢素)。
临床怎么用
- 所有患者均接受抗病毒治疗,73例(88%)联合局部糖皮质激素和/或环孢素。
- 作者认为局部环孢素可作为减少糖皮质激素用量的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Archipelago keratitis (ApK) is a subtype of Herpesviridae stromal keratitis that consists of subepithelial nummular inflammatory infiltrates arranged in a radial centripetal pattern. This rare and poorly described form is not often recognised early. We report the first large series of ApK, with an analysis of clinical settings at presentation, evolution of the disease with time and a description of factors associated with recurrence. METHODS: The clinical records of 82 patients (83 eyes) with a diagnosis of ApK between 2011 and 2021 in two centres were reviewed. RESULTS: The median age of the 82 patients at referral was 37±28 years. ApK was unilateral in all but one case. A total of 76% of patients had at least one second diagnostic criteria suggesting a herpetic aetiology. Overall, 44 (53%) eyes exhibited least one recurrence after a median of 12 months. Recurrence was frequently associated with neovascularisation (HR 2.1, 95% CI 1.1 to 3.9; p=0.02) and tapering corticosteroids (HR 3.5, 95% CI 1.8 to 7.1; p<0.01) or valaciclovir use (HR=2.3, 95% CI 1.2 to 4.6; p=0.01). Antiviral treatment was used in all patients, whereas local anti-inflammatory drugs such as corticosteroids and/or ciclosporin were used in 73 (88%) cases. CONCLUSION: ApK is a Herpesviridae stromal keratitis that is typically unilateral in presentation and features a high risk of recurrence. Combined treatment with antiviral and anti-inflammatory drugs are usually required over the long term. Topical ciclosporin can be useful as a corticosteroid-sparing treatment.
引用
- Guindolet D, Gemahling A, Rousseau A, et al. Clinical course and treatment of archipelago keratitis: a Herpesviridae keratitis subtype. Br J Ophthalmol. 2022. PMID: 35882515. doi:10.1136/bjo-2021-320847
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。